Dr. Ong is a physician and bioentrepreneur with over 20 years of clinical and drug development experience in pharma and biotech. He is currently Chief Executive Officer of Ring Therapeutics and prior to his current role, served as Senior Vice President at Biogen. Dr. Ong was also Chief Development Officer at Nightstar Therapeutics until its acquisition by Biogen. During this time, he was involved with the company’s public listing on the NASDAQ, corporate and gene therapy strategy, investor, and M&A activities. Dr. Ong has worked in the fields of genetics, ophthalmology, and rare disease at PTC Therapeutics Inc., Bausch and Lomb Inc. (acquired by Valeant Pharmaceuticals International, Inc.), and Pfizer.
He holds an MD from the University College London and an MBA from New York University Stern School of Business. Dr. Ong is also a member of the Royal College of Ophthalmologists and a Churchill Fellow.